Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population | BMC Cancer | Full Text

Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population | BMC Cancer | Full Text

Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population

The efficacy and safety of lapatinib plus capecitabine (LC or LX) versus trastuzumab plus chemotherapy in patients with HER-positive metastatic breast cancer who are resistant to trastuzumab is unknown.

Authors:Fan Yang, Xiang Huang, Chunxiao Sun, Jianbin Li, Biyun Wang, Min Yan, Feng Jin, Haibo Wang, Jin Zhang, Peifen Fu, Tianyu Zeng, Jian Wang, Wei Li, Yongfei Li, Mengzhu Yang, Jun Li…

Citation:BMC Cancer 2020 20:255

Content type:Research article

Published on: 29 March 2020

• ViewFull Text
 
• ViewPDF